JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Goldenberg, D. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Goldenberg, D. M.
Journal of Nuclear Medicine Vol. 43 No. 5 693-713
© 2002 by Society of Nuclear Medicine

Special Contribution

Targeted Therapy of Cancer with Radiolabeled Antibodies

David M. Goldenberg, ScD, MD1

Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, New Jersey

This review focuses on the use of radiolabeled antibodies in the therapy of cancer, termed radioimmunotherapy (RAIT). Basic problems concerning the choice of antibody and radionuclide and the physiology of tumor and host are discussed. Then follows a review of pertinent clinical publications on various radioantibody constructs in the treatment of hematopoietic and solid tumors of diverse histopathologies, grades, and stages, and in different clinical settings. Factors such as dose rate delivered, tumor size, and radiosensitivity play a major role in determining therapeutic response, while target-to-nontarget ratios and, particularly, circulating radioactivity to the bone marrow determine the major dose-limiting toxicities. RAIT appears to be gaining a place in the therapy of hematopoietic neoplasms, such as non-Hodgkin’s lymphoma, with several agents advancing in clinical trials toward registration, of which one has just been approved by the FDA. Although RAIT of solid tumors has shown less progress, pretargeting strategies, such as an affinity-enhancement system consisting of bispecific antibodies separating targeting from delivery of the radiotherapeutic, appear to enhance tumor-to-nontumor ratios and may increase rad doses to tumor more selectively than directly labeled antibodies.

Key Words: antibodies • cancer • radioimmunotherapy




This article has been cited by other articles:


Home page
 Anticancer ResHome page
N. XU, G. CAI, W. YE, X. WANG, Y. LI, P. ZHAO, A. ZHANG, R. ZHANG, and B. CAO
Molecular Imaging Application of Radioiodinated Anti-EGFR Human Fab to EGFR-overexpressing Tumor Xenografts
Anticancer Res, October 1, 2009; 29(10): 4005 - 4011.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
M. N. Chahine and G. N. Pierce
Therapeutic Targeting of Nuclear Protein Import in Pathological Cell Conditions
Pharmacol. Rev., September 1, 2009; 61(3): 358 - 372.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. M. Pagel, N. Orgun, D. K. Hamlin, D. S. Wilbur, T. A. Gooley, A. K. Gopal, S. I. Park, D. J. Green, Y. Lin, and O. W. Press
A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinations
Blood, May 14, 2009; 113(20): 4903 - 4913.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
J. H. Weisburg
Multidrug Resistance in Acute Myeloid Leukemia: Potential New Therapeutics
J. Nucl. Med., September 1, 2008; 49(9): 1405 - 1407.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. Martensson, R. Nilsson, T. Ohlsson, H.-O. Sjogren, S.-E. Strand, and J. Tennvall
Improved Tumor Targeting and Decreased Normal Tissue Accumulation through Extracorporeal Affinity Adsorption in a Two-Step Pretargeting Strategy
Clin. Cancer Res., September 15, 2007; 13(18): 5572s - 5576s.
[Abstract] [Full Text] [PDF]

Home page
 J. Histochem. Cytochem.Home page
S. C. Chauhan, N. Vinayek, D. M. Maher, M. C. Bell, K. A. Dunham, M. D. Koch, Y. Lio, and M. Jaggi
Combined Staining of TAG-72, MUC1, and CA125 Improves Labeling Sensitivity in Ovarian Cancer: Antigens for Multi-targeted Antibody-guided Therapy
J. Histochem. Cytochem., August 1, 2007; 55(8): 867 - 875.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
V. Tolmachev, A. Orlova, R. Pehrson, J. Galli, B. Baastrup, K. Andersson, M. Sandstrom, D. Rosik, J. Carlsson, H. Lundqvist, et al.
Radionuclide Therapy of HER2-Positive Microxenografts Using a 177Lu-Labeled HER2-Specific Affibody Molecule
Cancer Res., March 15, 2007; 67(6): 2773 - 2782.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
L. Martensson, R. Nilsson, T. Ohlsson, H.-O. Sjogren, S.-E. Strand, and J. Tennvall
Reduced Myelotoxicity with Sustained Tumor Concentration of Radioimmunoconjugates in Rats after Extracorporeal Depletion
J. Nucl. Med., February 1, 2007; 48(2): 269 - 276.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. N. Mamelak, S. Rosenfeld, R. Bucholz, A. Raubitschek, L. B. Nabors, J. B. Fiveash, S. Shen, M.B. Khazaeli, D. Colcher, A. Liu, et al.
Phase I Single-Dose Study of Intracavitary-Administered Iodine-131-TM-601 in Adults With Recurrent High-Grade Glioma
J. Clin. Oncol., August 1, 2006; 24(22): 3644 - 3650.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
G. Glatting, M. Muller, B. Koop, K. Hohl, C. Friesen, B. Neumaier, E. Berrie, P. Bird, G. Hale, N. M. Blumstein, et al.
Anti-CD45 Monoclonal Antibody YAML568: A Promising Radioimmunoconjugate for Targeted Therapy of Acute Leukemia
J. Nucl. Med., August 1, 2006; 47(8): 1335 - 1341.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
J. Elgqvist, H. Andersson, T. Back, I. Claesson, R. Hultborn, H. Jensen, B. R. Johansson, S. Lindegren, M. Olsson, S. Palm, et al.
{alpha}-Radioimmunotherapy of Intraperitoneally Growing OVCAR-3 Tumors of Variable Dimensions: Outcome Related to Measured Tumor Size and Mean Absorbed Dose
J. Nucl. Med., August 1, 2006; 47(8): 1342 - 1350.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
M. P. Kelly, F. T. Lee, F. E. Smyth, M. W. Brechbiel, and A. M. Scott
Enhanced Efficacy of 90Y-Radiolabeled Anti-Lewis Y Humanized Monoclonal Antibody hu3S193 and Paclitaxel Combined-Modality Radioimmunotherapy in a Breast Cancer Model
J. Nucl. Med., April 1, 2006; 47(4): 716 - 725.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. M. Goldenberg, R. M. Sharkey, G. Paganelli, J. Barbet, and J.-F. Chatal
Antibody Pretargeting Advances Cancer Radioimmunodetection and Radioimmunotherapy
J. Clin. Oncol., February 10, 2006; 24(5): 823 - 834.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
R. M. Reilly
Radioimmunotherapy of Solid Tumors: The Promise of Pretargeting Strategies Using Bispecific Antibodies and Radiolabeled Haptens
J. Nucl. Med., February 1, 2006; 47(2): 196 - 199.
[Full Text] [PDF]

Home page
 JNMHome page
F. Kraeber-Bodere, C. Rousseau, C. Bodet-Milin, L. Ferrer, A. Faivre-Chauvet, L. Campion, J.-P. Vuillez, A. Devillers, C.-H. Chang, D. M. Goldenberg, et al.
Targeting, Toxicity, and Efficacy of 2-Step, Pretargeted Radioimmunotherapy Using a Chimeric Bispecific Antibody and 131I-Labeled Bivalent Hapten in a Phase I Optimization Clinical Trial
J. Nucl. Med., February 1, 2006; 47(2): 247 - 255.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
M. Ferrari, M. Cremonesi, M. Bartolomei, L. Bodei, M. Chinol, M. Fiorenza, G. Tosi, and G. Paganelli
Dosimetric Model for Locoregional Treatments of Brain Tumors with 90Y-Conjugates: Clinical Application with 90Y-DOTATOC
J. Nucl. Med., January 1, 2006; 47(1): 105 - 112.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
I. Burvenich, S. Schoonooghe, B. Cornelissen, P. Blanckaert, E. Coene, C. Cuvelier, N. Mertens, and G. Slegers
In vitro and In vivo Targeting Properties of Iodine-123- or Iodine-131-Labeled Monoclonal Antibody 14C5 in a Non-Small Cell Lung Cancer and Colon Carcinoma Model
Clin. Cancer Res., October 15, 2005; 11(20): 7288 - 7296.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. Martensson, Z. Wang, R. Nilsson, T. Ohlsson, P. Senter, H.-O. Sjogren, S.-E. Strand, and J. Tennvall
Determining Maximal Tolerable Dose of the Monoclonal Antibody BR96 Labeled with 90Y or 177Lu in Rats: Establishment of a Syngeneic Tumor Model to Evaluate Means to Improve Radioimmunotherapy
Clin. Cancer Res., October 1, 2005; 11(19): 7104s - 7108s.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. M. Sharkey, H. Karacay, T. M. Cardillo, C.-H. Chang, W. J. McBride, E. A. Rossi, I. D. Horak, and D. M. Goldenberg
Improving the Delivery of Radionuclides for Imaging and Therapy of Cancer Using Pretargeting Methods
Clin. Cancer Res., October 1, 2005; 11(19): 7109s - 7121s.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. A. Rossi, C.-H. Chang, M. J. Losman, R. M. Sharkey, H. Karacay, W. McBride, T. M. Cardillo, H. J. Hansen, Z. Qu, I. D. Horak, et al.
Pretargeting of Carcinoembryonic Antigen-Expressing Cancers with a Trivalent Bispecific Fusion Protein Produced in Myeloma Cells
Clin. Cancer Res., October 1, 2005; 11(19): 7122s - 7129s.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. G. van Schaijk, E. Oosterwijk, A. C. Soede, M. Broekema, C. Frielink, W. J. McBride, D. M. Goldenberg, F. H.M. Corstens, and O. C. Boerman
Pretargeting of Carcinoembryonic Antigen-Expressing Tumors with a Biologically Produced Bispecific Anticarcinoembryonic Antigen x Anti-Indium-Labeled Diethylenetriaminepentaacetic Acid Antibody
Clin. Cancer Res., October 1, 2005; 11(19): 7130s - 7136s.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. H. Brouwers, W. C.A.M. Buijs, P. F.A. Mulders, P. H.M. de Mulder, W. J.M. van den Broek, C. Mala, E. Oosterwijk, O. C. Boerman, F. H.M. Corstens, and W. J.G. Oyen
Radioimmunotherapy with [131I]cG250 in Patients with Metastasized Renal Cell Cancer: Dosimetric Analysis and Immunologic Response
Clin. Cancer Res., October 1, 2005; 11(19): 7178s - 7186s.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. H. Brouwers, P. F.A. Mulders, P. H.M. de Mulder, W. J.M. van den Broek, W. C.A.M. Buijs, C. Mala, F. B.M. Joosten, E. Oosterwijk, O. C. Boerman, F. H.M. Corstens, et al.
Lack of Efficacy of Two Consecutive Treatments of Radioimmunotherapy With 131I-cG250 in Patients With Metastasized Clear Cell Renal Cell Carcinoma
J. Clin. Oncol., September 20, 2005; 23(27): 6540 - 6548.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. Liersch, J. Meller, B. Kulle, T. M. Behr, P. Markus, C. Langer, B. M. Ghadimi, W. A. Wegener, J. Kovacs, I. D. Horak, et al.
Phase II Trial of Carcinoembryonic Antigen Radioimmunotherapy With 131I-Labetuzumab After Salvage Resection of Colorectal Metastases in the Liver: Five-Year Safety and Efficacy Results
J. Clin. Oncol., September 20, 2005; 23(27): 6763 - 6770.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
F. G. van Schaijk, M. Broekema, E. Oosterwijk, J. E.M. van Eerd, B. J. McBride, D. M. Goldenberg, F. H.M. Corstens, and O. C. Boerman
Residualizing Iodine Markedly Improved Tumor Targeting Using Bispecific Antibody-Based Pretargeting
J. Nucl. Med., June 1, 2005; 46(6): 1016 - 1022.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
R. M. Sharkey and D. M. Goldenberg
Perspectives on Cancer Therapy with Radiolabeled Monoclonal Antibodies
J. Nucl. Med., January 1, 2005; 46(1_suppl): 115S - 127S.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
E. Dadachova, A. Nakouzi, R. A. Bryan, and A. Casadevall
Ionizing radiation delivered by specific antibody is therapeutic against a fungal infection
PNAS, September 16, 2003; 100(19): 10942 - 10947.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. J. Buchsbaum, T. Zhou, W. E. Grizzle, P. G. Oliver, C. J. Hammond, S. Zhang, M. Carpenter, and A. F. LoBuglio
Antitumor Efficacy of TRA-8 Anti-DR5 Monoclonal Antibody Alone or in Combination with Chemotherapy and/or Radiation Therapy in a Human Breast Cancer Model
Clin. Cancer Res., September 1, 2003; 9(10): 3731 - 3741.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. M. Goldenberg
Introduction to the Ninth Conference on Cancer Therapy with Antibodies and Immunoconjugates
Clin. Cancer Res., September 1, 2003; 9(10): 3819s - 3820s.
[Full Text]

Home page
 Clin. Cancer Res.Home page
M. D. Winthrop, S. J. DeNardo, H. Albrecht, G. R. Mirick, L. A. Kroger, K. R. Lamborn, C. Venclovas, M. E. Colvin, P. A. Burke, and G. L. DeNardo
Selection and Characterization of Anti-MUC-1 scFvs Intended for Targeted Therapy
Clin. Cancer Res., September 1, 2003; 9(10): 3845s - 3853s.
[Abstract] [Full Text]

Home page
 Clin. Cancer Res.Home page
S. J. DeNardo, Z. Yao, K. S. Lam, A. Song, P. A. Burke, G. R. Mirick, K. R. Lamborn, R. T. O'Donnell, and G. L. DeNardo
Effect of Molecular Size of Pegylated Peptide on the Pharmacokinetics and Tumor Targeting in Lymphoma-Bearing Mice
Clin. Cancer Res., September 1, 2003; 9(10): 3854s - 3864s.
[Abstract] [Full Text]

Home page
 Clin. Cancer Res.Home page
E. A. Rossi, R. M. Sharkey, W. McBride, H. Karacay, L. Zeng, H. J. Hansen, D. M. Goldenberg, and C.-H. Chang
Development of New Multivalent-bispecific Agents for Pretargeting Tumor Localization and Therapy
Clin. Cancer Res., September 1, 2003; 9(10): 3886s - 3896s.
[Abstract] [Full Text]

Home page
 Clin. Cancer Res.Home page
H. Andersson, J. Elgqvist, G. Horvath, R. Hultborn, L. Jacobsson, H. Jensen, B. Karlsson, S. Lindegren, and S. Palm
Astatine-211-labeled Antibodies for Treatment of Disseminated Ovarian Cancer: An Overview of Results in an Ovarian Tumor Model
Clin. Cancer Res., September 1, 2003; 9(10): 3914s - 3921s.
[Abstract] [Full Text]

Home page
 Clin. Cancer Res.Home page
F. Kraeber-Bodere, A. Faivre-Chauvet, L. Ferrer, J.-P. Vuillez, P.-Y. Brard, C. Rousseau, I. Resche, A. Devillers, S. Laffont, M. Bardies, et al.
Pharmacokinetics and Dosimetry Studies for Optimization of Anti-Carcinoembryonic Antigen x Anti-Hapten Bispecific Antibody-mediated Pretargeting of Iodine-131-labeled Hapten in a Phase I Radioimmunotherapy Trial
Clin. Cancer Res., September 1, 2003; 9(10): 3973s - 3981s.
[Abstract] [Full Text]

Home page
 JNMHome page
S. Palm, R. M. Enmon Jr., C. Matei, K. S. Kolbert, S. Xu, P. B. Zanzonico, R. L. Finn, J. A. Koutcher, S. M. Larson, and G. Sgouros
Pharmacokinetics and Biodistribution of 86Y-Trastuzumab for 90Y Dosimetry in an Ovarian Carcinoma Model: Correlative MicroPET and MRI
J. Nucl. Med., July 1, 2003; 44(7): 1148 - 1155.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
A. A. Jungbluth, E. Stockert, H. J. S. Huang, V. P. Collins, K. Coplan, K. Iversen, D. Kolb, T. J. Johns, A. M. Scott, W. J. Gullick, et al.
A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor
PNAS, January 21, 2003; 100(2): 639 - 644.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Z. Yao, M. Zhang, D. B. Axworthy, K. J. Wong, K. Garmestani, L. Park, C. W. Park, R. W. Mallett, L. J. Theodore, E. K. Yau, et al.
Radioimmunotherapy of A431 Xenografted Mice with Pretargeted B3 Antibody-Streptavidin and 90Y-labeled 1,4,7,10-Tetraazacyclododecane-N,N',N'',N'''-tetraacetic Acid (DOTA)-Biotin
Cancer Res., October 15, 2002; 62(20): 5755 - 5760.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2002 by the Society of Nuclear Medicine.